https://orcid.org/0000-0003-3380-3080
References
- Tekgündüz E, Şencan İ, Kapuağası A, et al. Hematopoietic cell transplantation activity of Turkey in 2014: Ongoing increase in HCT rates. Transfus Apher Sci. 2016;54(1):53–59.
- Passweg JR, Baldomero H, Bader P, et al. European Society for Blood and Marrow Transplantation (EBMT), Hematopoietic SCT in Europe 2013: recent trends in the use of alternative donors showing more haploidentical donors but fewer cord blood transplants. Bone Marrow Transplant. 2015;50(4):476–482.
- Lucarelli G, Galimberti M, Polchi P, et al. Bone marrow transplantation in patients with thalassemia. N Engl J Med. 1990;322(7):417–421.
- Tiercy JM. How to select the best available related or unrelated donor of hematopoietic stem cells? Haematologica. 2016;101(6):680–687.
- Hamidieh AA, Ostadali Dehaghi M, Paragomi P, et al. Efficiency of allogeneic hematopoietic SCT from HLA fully-matched non-sibling relatives: a new prospect of exploiting extended family search. Bone Marrow Transplant. 2015;50(4):545–552.
- Aydinok Y. Thalassemia. Hematology. 2012;17(sup1):S28–S31.
- Taher AT, Weatherall DJ, Cappellini MD. Thalassaemia. Lancet. 2018;391(10116):155–167.
- Yesilipek MA, Ertem M, Cetin M, et al. HLA-matched family hematopoetic stem cell transplantation in children with beta thalassemia major: the experience of the Turkish Pediatric Bone Marrow Transplantation Group. Pediatr Transplant. 2012;16(8):846–851.
- Töret E, Karadaş NÖ, Gökçe NÖ, et al. Quality of life and depression in Turkish patients with β-thalassemia major: a cross-sectional study. Hemoglobin. 2018;42(5-6):326–329.
- Gaziev J, Marziali M, Isgrò A, et al. Bone marrow transplantation for thalassemia from alternative related donors: improved outcomes with a new approach. Blood. 2013;122(15):2751–2756.
- Korula A, Devasia AJ, Fouzia NA, et al. Outcomes following allogeneic stem cell transplantation using non-sibling family donors. Indian J Hematol Blood Transfus. 2019;35(1):43–49.
- Gaziev D, Galimberti M, Lucarelli G, et al. Bone marrow transplantation from alternative donors for thalassemia: HLA-phenotypically identical relative and HLA-nonidentical sibling or parent transplants. Bone Marrow Transplant. 2000;25(8):815–821.
- İleri T, Ünal İnce E, Çakmaklı H, et al. Evaluation of engraftment syndrome in children following full-matched related donor hematopoietic stem cell transplantations. Pediatr Transplant. 2016;20(4):581–589.
- Korula A, Pn N, Devasia A, et al. Second hematopoietic stem cell transplant for thalassemia major: improved clinical outcomes with a treosulfan-based conditioning regimen. Biol Blood Marrow Transplant. 2018;24(1):103–108.
- Jabbour E, Rondon G, Anderlini P, et al. Treatment of donor graft failure with nonmyeloablative conditioning of fludarabine, antithymocyte globulin and a second allogeneic hematopoietic transplantation. Bone Marrow Transplant. 2007;40(5):431–435.
- Li C, Mathews V, Kim S, et al. Related and unrelated donor transplantation for β-thalassemia major: results of an international survey. Blood Adv. 2019;3(17):2562–2570.
- Swaminathan VV, Uppuluri R, Patel S, et al. Matched family versus alternative donor hematopoietic stem cell transplantation for patients with thalassemia major: experience from a tertiary referral center in South India. Biol Blood Marrow Transplant. 2020;26(7):1326–1331.
- Bernardo ME, Piras E, Vacca A, et al. Allogeneic hematopoietic stem cell transplantation in thalassemia major: results of a reduced-toxicity conditioning regimen based on the use of treosulfan. Blood. 2012;120(2):473–476.
- Baronciani D, Angelucci E, Potschger U, et al. Hemopoietic stem cell transplantation in thalassemia: a report from the European Society for Blood and Bone Marrow Transplantation Hemoglobinopathy Registry, 2000–2010. Bone Marrow Transplant. 2016;51(4):536–541.